Prestige Biologics Co., Ltd. (KOSDAQ:334970)
1,057.00
-42.00 (-3.82%)
At close: Nov 20, 2026
Prestige Biologics Revenue
In the fiscal year ending June 30, 2026, Prestige Biologics had annual revenue of 26.67B KRW with 112.75% growth. Prestige Biologics had revenue of 14.32B in the quarter ending June 30, 2026, with 151.86% growth. That makes Prestige Biologics the 33,974th largest company in the world by revenue and 2,166th in South Korea.
Revenue
26.67B
Revenue Growth
+112.75%
P/S Ratio
3.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
82.18B
Revenue by Segment
- Antibody Drugs 1.48B 68.2%
- Other than Service 689.62M 31.8%
Fiscal year ended Jun 30, 2024 See the full Prestige Biologics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 26.67B | 14.13B | 112.75% |
| Jun 30, 2025 | 12.53B | 10.36B | 477.83% |
| Jun 30, 2024 | 2.17B | 423.21M | 24.24% |
| Jun 30, 2023 | 1.75B | 1.73B | 11,115.88% |
| Dec 31, 2022 | 15.57M | -3.21B | -99.52% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 130.99B |
| Cell Biotech | 60.40B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 18.72B |
| TiumBio | 15.68B |
| EyeGene | 4.48B |
| CHOOLIP & SCIENCES | 1.08B |